The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 1.02 percent decrease over the last five trading days and ended the week at 3,064.87 points. The Index is up 10.54 percent year-to-date.
Last week the US Senate confirmed Scott Gottlieb as head of the US Food and Drug Administration. A new report on the pharma industry revealed, despite many pricing controversies last year, products in these sector continue to sell at high prices. STAT News reported on how the massive cyberattack from last week “crippled” hospital networks in the UK.
Sangamo Therapeutics (NASDAQ:SGMO)
Durect (NASDAQ:DRRX)
Merus Labs International (NASDAQ:MSLI)
MannKind (NASDAQ:MNKD)
NantKwest (NASDAQ:NK)
Sangamo Therapeutics
Sangamo is a clinical-stage biotechnology company focused on working with genomic therapies like genome editing, gene therapy, gene regulation and cell therapy. Last week’s rise in Sangamo’s stock was due to the announcement of a partnership between the company and Pfzer (NASDAQ:) to develop and commercialize gene therapy program for Hemophilia A.
Sangamo also released their financial report for the second quarter of the year. “Three Phase 1/2 in vivo genome editing clinical trials are now screening subjects, and the fourth trial evaluating SB-525, a cDNA gene therapy approach for Hemophilia A, will open later this quarter,” Dr. Sandy Macrae, CEO of Sangamo, said in a statement.
Sangamo Therapeutics gained 80.22 percent last week to finish at $8.20 per share.
Durect
Durect is a biopharmaceutical company with two commercial products and an extensive pipeline of products, including two on at the NDA stage. Similarly to Sangamo, last week Durect released a set of financial results and a revealed $239 million development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE:NVS).
“Recent enrollment rates for PERSIST, the POSIMIR pivotal Phase 3 clinical trial in post-operative pain, are ahead of schedule and support completion of dosing in the second quarter of 2017,” said president and CEO of DURECT James E. Brown in a statement.
Durect gained 51.25 percent last week to finish at $1.21 per share.
Merus Labs International
Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of branded prescription pharmaceutical products. Last week the company shared it had entered a definitive arrangement agreement with Norgine. In this deal Norgine will acquire all common shares of Merus for a total of approximately $342 million.
As part of a statement for their latest financial results report to investors, Barry Fishman CEO of Merus, said the company was on track to deliver on their plans for 2017. The company’s revenue saw an increase in revenue from last year’s second quarter total of 19.7 million to this year 22.6 million.
Merus Labs International gained 48.88 percent last week to finish at $1.18 per share.
MannKind
MannKind is a pharmaceutical company developing therapeutic products for diabetes and other diseases. The week started strong for the company seeing their highest trading day Wednesday May 10, where its stock closed at $1.60. Despite that later in the week the company released their financial results for the first quarter of the year, indicating a $16.3 million loss. With its lead product Afrezza producing $1.2 million in revenue.
The press release contained no statement from the company’s CEO and CFO Matthew J. Pfeffer.
MannKind gained 40.49 percent last week to finish at $1.12 per share.
NantKwest
NantKwest is a clinical-stage immunotherapy company working to treat cancer, infectious diseases and inflammatory diseases. Last week the company revealed it had received authorization from the US Food and Drug Administration.
NantKwest gained 35.84 percent last week to finish at $3.98 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 0.58 percent decrease over the last five trading days and ended the week at 3,096.41 points. The Index is up 11.67 percent year-to-date.
Last week House Republicans finally managed to pass a health care bill, that has caused outrage against it and the process behind the vote of it. Mexico voted on legalizing the use of cannabis for medical and scientific reasons, a move that could benefit Canadian companies looking to expand their business. FierceBiotech reported on Seattle Genetics’ (NASDAQ:SGEN) decision to scrap a deal with Immunomedics (NASDAQ:IMMU) due to the removal from the latter’s CEO Cynthia Sullivan. Following the vote on the new health care reforms, multiple reports of inside notes inside the bill like a defunding of the reproductive health care group Planned Parenthood and the removal of $1 billion from the Centers for Disease Control and Prevention budget.
- Span-America Medical Systems (NASDAQ:SPAN)
- Myriad Genetics (NASDAQ:MYGN)
- Concordia International (NASDAQ:CXRX)
- EXACT Sciences (NASDAQ:EXAS)
- ChromaDex Corporation (NASDAQ:CDXC)
- Span-America Medical Systems
- Span-America Medical Systems manufactures therapeutic equipment for the medical market like medical bed frames or wheelchair cushions. Last week the company presented their financials for the fiscal second quarter of 2017, revealing a sales increase of three percent to $15.2 million. The company also announced an acquisition deal, which would see it get absorbed by Savaria Corporation (TSX:SIS) for approximately $80.2 million.
- Span-America Medical Systems gained 32.97 percent last week to finish at $28.96 per share.
- Myriad Genetics
- Myriad Genetics is a molecular diagnostic company working on the development of those same tests, these can look at the possibility of patients to develop various diseases at one point in their lives. The company revealed their financial numbers for the fiscal third quarter of 2017, which saw a total revenue of 196.9 million and an increase in their hereditary cancer testing.
- Myriad will also be doing four presentations on prostate cancer at the annual meeting of the American Urological Association.
- Myriad Genetics gained 21.70 percent last week to finish at $22.38 per share.
- Concordia
- Concordia is a pharmaceutical selling branded and generic prescription products and seeks on the acquisition, licensing and development of development in off-patent prescription medicines and orphan drugs.
- Last week the company announced the appointment of two new board members this year. However, there has been no further recent news from the company to explain last week’s rise in share price.
- Concordia International gained 19.44percent last week to finish at $1.51 per share.
- EXACT Sciences
- Staying strong after being featured in last week’s top gainers, EXACT works on the detection and prevention of various cancers through molecular diagnostics.
- Last week analysts at Cowen Insight surveyed doctors in the area and concluded the company could reach a $700 million revenue mark in 2019 thanks to Cologuard, which uses feces to test for colon cancer.
- EXACT Sciences gained 18.06 percent last week to finish at $35.43 per share.
- Chroma Dex
- Chroma Dex also managed to stay on the top gainers this week, albeit it went from first place to last. The company holds a portfolio of health products and supplements.
- Last week the company announced it would be disclosing its financial results for the first quarter of 2017 on May 11. However, there has been no further recent news from the company to explain last week’s rise in share price.
- ChromaDex gained 16.08 percent last week to finish at $3.61 per share.
- The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a 3.5 percent increase over the last five trading days and ended the week at 3,114.67 points. The Index is up 12.33 percent year-to-date.
- Last week the GOP failed again to bring a potentially viable health care bill onto the floor of Congress, the market has been settling into these weekly attempts and chatter of a re-introduction of an Obamacare replacement. The US Food and Drug Administration approved a new treatment for acute myeloid leukemia to Novartis Pharmaceuticals (VTX:NOVN). BioMarin Pharmaceutical (NASDAQ:BMRN) also received approval for a form of Batten disease treatment.
- ChromaDex Corporation (NASDAQ:CDXC)
- EXACT Sciences (NASDAQ:EXAS)
- Epizyme (NASDAQ:EPZM)
- Sangamo Therapeutics (NASDAQ:SGMO)
- LeMaitre Vascular (NASDAQ:LMAT)
- ChromaDex Corporation
- ChromaDex is a company looking to develop ingredient technologies for a variety of health improvements. They hold an extensive portfolio of health supplements and products. Last week the company announced the sale of up to $25 million in common stock to Hong Kong billionaire Li Ka-Shing.
- ChromaDex gained 36.40 percent last week to finish at $3.11 per share.
- EXACT Sciences
- EXACT Sciences is a molecular diagnostics company, they work on detection and prevention of some types of cancer. The company revealed their financial results for the first quarter of the year last week, indicating a revenue stream of $48.4 million and the completion of 470,000 clonguard tests, the company’s colon cancer trial.
- EXACT Sciences gained 25.41 percent last week to finish at $30.01 per share.
- Epizyme
- This clinical-stage biopharmaceutical is working on epigenetic therapies for cancer patients. The US Food and Drug Administration granted a Fast Track designation to tazemetostat treating lymphoma, meaning it may reduce development time and costs when bringing a drug to market.
- Epizyme gained 24.05 percent last week to finish at $18.05 per share.
- Sangamo Therapeutics
- Sangamo is a clinical-stage biotechnology company using genetic therapy and has partnered to expedite clinical and commercial development. Last week the company announced it would be presenting at the American Society of Gene & Cell Therapy meeting. Their founder and chairman Edward Lanphier announced he would be retiring following a year-long transition process in the company. However, there has been no further recent news from the company to explain last week’s rise in share price.
- Sangamo Therapeutics gained 18.52 percent last week to finish at $4.80 per share.
- LeMaitre Vascular
- LeMaitre is a medical device company working on peripheral vascular disease. Last week the company revealed their financials for the first quarter of the year, with it the announcement that revenue increases 19 percent to 24.1 million. While earnings per share went up 42 percent.
- LeMaitre Vascular gained 18.34 percent last week to finish at $29.75 per share
No comments:
Post a Comment